1. Novartis CEO Narasimhan touts blockbuster pipeline — Eli Lilly’s generic insulin to be half the price of branded counterpart — JNJ’s Invokana closes in on diabetic kidney disease approval -- See more on our front page news

    Got questions about whistleblowing?: Ask a Whistleblower Attorney
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 23, 2019 at 5:52 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    10,443
    Likes Received:
    3
    via With shareholder resolutions at six top U.S. drugmakers—AbbVie, Celgene, Johnson & Johnson, Merck & Co., Pfizer and Vertex—the investors aim to learn how price changes factor into sales goals and other exec pay metrics. The resolutions, up for votes at the companies' annual meetings, ask the drugmakers whether they use price increases to meet their sales goals, whether boards must approve price hikes, and more.

    article source